ATF3, a novel cardiac therapeutic target: Beneficial or harmful?

Kalfon, R; Koren, L; Aronheim, A

Kalfon, R; Koren, L; Aronheim, A.

Afiliação

Kalfon R; Department of Cell Biology and Cancer Science, The B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Koren L; Department of Cell Biology and Cancer Science, The B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Aronheim A; Department of Cell Biology and Cancer Science, The B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: aronheim@tx.technion.ac.il.

Int J Cardiol ; 234: 124, 2017 05 01.

Article em En | MEDLINE | ID: mdl-28082095

Assuntos

Fator 3 Ativador da Transcrição; Coração; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator 3 Ativador da Transcrição / Coração Limite: Humans Idioma: En Revista: Int J Cardiol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Israel

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google